Exciting news for patients and healthcare professionals: new clinical trial sites are now open in Chicago and Dallas, enhancing access to cutting-edge medical research and treatments.
We are thrilled to announce the opening of new clinical trial sites in Chicago, IL, and Dallas, TX. These sites will serve as hubs for groundbreaking medical research, offering patients access to the latest advancements in healthcare. By expanding our network, we aim to bring innovative treatments and therapies closer to those who need them most.
Our new sites are equipped with state-of-the-art facilities and staffed by highly skilled professionals dedicated to advancing medical science. This expansion underscores our commitment to improving patient outcomes through rigorous clinical research and collaboration.
Clinical trials are essential for the development of new treatments and therapies. They provide critical data that helps determine the safety and efficacy of new medical interventions. By participating in clinical trials, patients play a crucial role in the advancement of healthcare, contributing to discoveries that can benefit future generations.
Our clinical trials adhere to the highest standards of scientific integrity and patient safety. We work closely with regulatory bodies to ensure that our studies are conducted ethically and transparently. Through these efforts, we aim to accelerate the availability of new treatments and improve the quality of life for patients worldwide.
Dr. Samuel Moltz – Chicago Site
Our Chicago site is led by Dr. Samuel Moltz, a board-certified Internal Medicine physician with over two decades of experience across academic and clinical settings in the Chicagoland area. A graduate of Washington University in St. Louis and Loyola University Stritch School of Medicine, he completed his residency at Rush University Medical Center. Dr. Moltz has focused his career on medical education, quality patient care, and integrative medicine. He is a member of the American Academy of Environmental Medicine (AAEM) and the American College for Advancement in Medicine (ACAM), and he remains actively involved in the field through ongoing participation in regional and national conferences.
Dr. Diana Castro – Dallas Site
Our Dallas site is led by Dr. Diana Castro, a board-certified neurologist and neuromuscular physician with a nationally recognized reputation in the research and management of rare neuromuscular conditions. With extensive clinical trial experience in Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dr. Castro is deeply committed to advancing therapies for both pediatric and adult patients. She is known for the strong, lasting relationships she builds with her patients and their families—connections that fuel her mission to expand access to care and innovative treatments. A frequent national and international speaker, Dr. Castro has authored numerous peer-reviewed publications and serves on several medical advisory boards and steering committees. After more than a decade in academia, she founded a non-profit neuromuscular practice and research institute, dedicated to providing comprehensive care regardless of a patient’s insurance status or location.
We are excited to announce that our Chicago site is now enrolling participants for a neuropathic pain clinical study. This study aims to explore new treatment options for patients suffering from chronic neuropathic pain, a condition that significantly impacts quality of life. By joining this study, participants will have access to cutting-edge therapies and contribute to important medical research.
Patients interested in participating in the neuropathic pain clinical study can contact our Chicago site for more information on eligibility and enrollment. We are committed to providing a supportive and informative experience for all our study participants.
As we continue to expand our clinical trial network, we remain focused on our mission to advance medical knowledge and improve patient outcomes. Our new sites in Chicago and Dallas represent just the beginning of our efforts to make cutting-edge research accessible to more communities.
We are excited about the future of clinical research and the potential it holds for transforming healthcare. By fostering collaboration and innovation, we aim to lead the way in developing new treatments and therapies that can change lives.